Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 2/20 | 0.54 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.54 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.54 |
| ▸ | CBFB | Q13951 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 10/20 | 0.49 |
| ▸ | NPC1 | O15118 | 8/20 | 0.49 |
| ▸ | RAB9A | P51151 | 8/20 | 0.49 |
| ▸ | HPGD | P15428 | 5/20 | 0.49 |
| ▸ | PKM | P14618 | 5/20 | 0.49 |
| ▸ | METAP2 | P50579 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | METAP1 | P53582 | 2/20 | 0.49 |
| ▸ | MTOR | P42345 | 1/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.47 |
| ▸ | TP53 | P04637 | 5/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13373477 | 0.79 | HRH3 (0.44) | FGFR1FGFR2FGFR3SMN1; SMN2NPC1 | |
| SCHEMBL1528347 | 0.78 | NPC1 (0.58) | FGFR1FGFR2FGFR3SMN1; SMN2NPC1 | |
| SCHEMBL22488748 | 0.77 | SMN1; SMN2 (0.56) | FGFR1FGFR2FGFR3SMN1; SMN2NPC1 | |
| SCHEMBL25425247 | 0.77 | FOXO1 (0.59) | FGFR1FGFR2FGFR3SMN1; SMN2NPC1 | |
| SCHEMBL30754028 | 0.77 | FOXO1 (0.59) | FGFR1FGFR2FGFR3SMN1; SMN2NPC1 | |
| SCHEMBL5952231 | 0.75 | NPC1 (0.58) | FGFR1FGFR2FGFR3SMN1; SMN2NPC1 | |
| SCHEMBL13373870 | 0.73 | NPC1 (0.51) | FGFR1FGFR2FGFR3SMN1; SMN2NPC1 | |
| SCHEMBL5951313 | 0.73 | FGFR1 (0.54) | FGFR1FGFR2FGFR3SMN1; SMN2NPC1 | |
| SCHEMBL2374336 | 0.73 | L3MBTL1 (0.53) | NPC1RAB9ALMNAADORA3ADORA2A | |
| SCHEMBL13348557 | 0.72 | BTK (0.54) | FGFR1FGFR2FGFR3SMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060014756-A1 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2006-01-19 | — | — | US | claimed |
| US-6897208-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2005-05-24 | — | — | US | claimed |
| EP-1441725-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2004-08-04 | — | — | EP | claimed |
| US-20040048868-A1 | Benzimidazoles | AVENTISUB LLC | 2004-03-11 | — | — | US | claimed |
| WO-2003035065-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | AVENTIS PHARMACEUTICALS INC (US) | 2003-05-01 | — | — | WO | claimed |
| US-8288425-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-8288425-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-8288425-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-20060014756-A1 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2006-01-19 | — | — | US | disclosed |
| US-6897208-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2005-05-24 | — | — | US | disclosed |
| EP-1441725-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2004-08-04 | — | — | EP | disclosed |
| US-20040048868-A1 | Benzimidazoles | AVENTISUB LLC | 2004-03-11 | — | — | US | disclosed |
| WO-2003035065-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | AVENTIS PHARMACEUTICALS INC (US) | 2003-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014756-A1 | Benzimidazoles | CDK9, BMX, SBK3 | FGFR1 583/4885FGFR2 757/4885FGFR3 532/4885 |
| US-20040048868-A1 | Benzimidazoles | CDK9, BMX, CDKN1A | FGFR1 254/4885FGFR2 600/4885FGFR3 464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.